Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Medical Officer | February 24, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date February 24, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,968 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Sale · Disposed 4,582 · Balance 159,968 F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,582 | $14.47 | $66,301.54 |
DisclosureSEC source: 0001193125-26-072000 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,968 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,982 | $13.62 | $67,854.84 |
DisclosureSEC source: 0001193125-26-064257 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,550 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059640 · ownership.xml · derivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,632 | $9.67 | $44,791.44 |
DisclosureSEC source: 0001193125-25-327030 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,532 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,895 | $8.53 | $41,754.35 |
DisclosureSEC source: 0000950170-25-029201 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,164 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000950170-25-025028 · ownership.xml · derivative · entry 2 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-025028 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,059 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,632 | $11.41 | $52,851.12 |
DisclosureSEC source: 0000950170-24-139124 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,059 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0000950170-24-019455 · ownership.xml · derivative · entry 2 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-22 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-019455 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,691 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,860 | $8.50 | $15,810.00 |
DisclosureSEC source: 0000950170-23-072756 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,191 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 386 | $8.22 | $3,172.92 |
DisclosureSEC source: 0000950170-23-071987 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,051 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:17 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 387 | $12.94 | $5,007.78 |
DisclosureSEC source: 0000950170-23-029161 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,437 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:46 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 394 | $8.76 | $3,451.44 |
DisclosureSEC source: 0000899243-23-013361 · doc4.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,824 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:38 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 392 | $10.71 | $4,198.32 |
DisclosureSEC source: 0000950170-23-013705 · ownership.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,218 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| March 20, 2023 Filed Mar 27, 2023 20:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 390 | $11.32 | $4,414.80 |
DisclosureSEC source: 0000899243-23-009717 · doc4.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,610 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:51 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0000899243-23-005728 · doc4.xml · derivative · entry 2 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-02-16 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 23:51 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005728 · doc4.xml · nonDerivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · shares: The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0000899243-22-008730 · doc4.xml · derivative · entry 1 Jones Jeffrey Alan · CIK 0001914647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option represents a right to purchase a total of 215,000 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on February 28, 2023, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.